Department of Dermatology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Expert Rev Clin Pharmacol. 2023 Jan-Jun;16(6):601-611. doi: 10.1080/17512433.2023.2213887. Epub 2023 May 23.
Compound glycyrrhizin (CG) is widely used to treat vitiligo in China, and the efficacy and adverse events (AEs) of CG for vitiligo need further analysis. This study aimed to systematically reevaluate the efficacy and safety of CG in the patients with vitiligo.
Eight literature databases were searched up to 31 December 2022, and randomized controlled trials which compared CG plus conventional treatments with conventional treatments alone were included.
17 studies with 1492 patients were included. The pooled results showed that the combination of CG and conventional treatments was superior to conventional treatments alone in the total efficacy rate (risk ratio (RR) = 1.54, 95% confidence interval (CI) = 1.40 to 1.69, < 0.00001), cure rate (RR = 1.62, 95%CI = 1.32 to 1.99, < 0.00001), the levels of serum IL-6, TNF-α, IL-17, and TGF-ß, and the ratio of CD4/CD8 T cell in blood. Moreover, few patients suffered from the mild and tolerable AEs of CG.
CG plus conventional treatments is an effective treatment for vitiligo with mild and tolerable AEs. More high-quality and large-sample studies are required in the future to provide more evidence of CG for vitiligo.
CRD42023401166.
复方甘草酸苷（CG）在中国被广泛用于治疗白癜风，其治疗白癜风的疗效和不良反应（AE）需要进一步分析。本研究旨在系统评价 CG 治疗白癜风的疗效和安全性。
检索截至 2022 年 12 月 31 日的 8 个文献数据库，纳入 CG 联合常规治疗与单纯常规治疗比较的随机对照试验。
纳入 17 项研究共 1492 例患者。汇总结果显示，CG 联合常规治疗在总有效率（风险比（RR）=1.54，95%置信区间（CI）=1.40 至 1.69， < 0.00001）、治愈率（RR=1.62，95%CI=1.32 至 1.99， < 0.00001）、血清白细胞介素-6（IL-6）、肿瘤坏死因子-α（TNF-α）、白细胞介素-17（IL-17）和转化生长因子-β（TGF-ß）水平以及血 CD4+/CD8+T 细胞比值方面均优于单纯常规治疗，且 CG 的不良反应较轻且可耐受。
CG 联合常规治疗是一种治疗白癜风有效且不良反应较轻且可耐受的方法。未来需要更多高质量、大样本的研究来为 CG 治疗白癜风提供更多证据。
PROSPERO 注册号：CRD42023401166。
